illumicell AI is a technology company.
illumicell AI has raised $300K across 1 funding round.
illumicell AI has raised $300K in total across 1 funding round.
illumicell AI has raised $300K in total across 1 funding round.
illumicell AI's investors include Arix Bioscience, Canaan Partners.
illumicell AI is a biotech startup developing a portable AI-powered lab scanner for real-time analysis of cellular dynamics in bodily fluids, starting with male fertility diagnostics.[1][2][5] The company combines proprietary imaging hardware and AI algorithms to deliver lab-grade results 50 times faster and at 20 times lower cost than traditional methods, targeting healthcare providers and patients facing infertility delays—where less than 25% of men globally receive proper evaluations.[2] It serves doctors' offices, clinics, and patients directly, solving bottlenecks in fluid-based diagnostics by enabling on-site testing and generating structured cell data for personalized insights, with initial applications in sperm analysis and expansion potential to immune system monitoring and cancer therapies.[1][2]
The platform has raised $2M in funding and built a dataset of over 400,000 data points from scans, fueling AI improvements and applications like tracking lifestyle impacts on fertility or early decline detection.[2] As a Harvard Innovation Labs alumni venture, illumicell AI is gaining early traction through studies and cohorts like Launch Lab X GEO.[3][5]
Founded in Zurich, Switzerland, illumicell AI emerged from the need to make cellular diagnostics faster and more accessible, with co-founders Dr. Michel Bielecki (CEO) and Jeyla Sadikova (COO & Co-Founder) leading the effort.[1][2] Bielecki, emphasizing real-time lab-grade testing in any doctor's office, highlighted how the technology addresses infertility testing delays and costs, turning each scan into a feedback loop for clinicians and AI training.[2]
The idea crystallized around proprietary microscopy and patented AI for visualizing cell behavior in real time, starting with male fertility but rooted in broader biotech applications like immune system analysis.[1][4] Early momentum includes a $2M raise in April 2025 to scale the portable sperm scanner, participation in Harvard Innovation Labs' 2023-2024 Launch Lab X GEO cohort as an alumni startup, and ongoing Harvard studies recruiting participants to build its dataset.[2][3][5]
illumicell AI rides the wave of AI-driven personalized diagnostics and point-of-care biotech, capitalizing on surging demand for at-home and rapid fertility testing amid global infertility affecting 1 in 6 couples.[2] Timing aligns with AI maturation in healthcare imaging—post-2025 funding boom—and hardware miniaturization, enabling portable alternatives to centralized labs strained by backlogs.[2]
Market tailwinds include regulatory pushes for accessible repro health, AI's role in drug development (e.g., faster cancer therapies via immune data), and datasets fueling precision medicine.[1][2] By democratizing cellular intelligence, it influences the ecosystem: empowers pharma with trainable immune insights, clinicians with instant data, and patients with proactive health tracking, potentially disrupting $multi-billion diagnostics markets from fertility to oncology.[1][2]
illumicell AI is poised to expand from fertility flagship to multi-fluid platform, leveraging its dataset for lifestyle/early-detection apps and adjacent fields like immunology or oncology.[1][2] Key trends—AI hardware convergence, reprotech investment surge, and personalized med data loops—will accelerate growth, with partnerships (e.g., Harvard studies) and funding enabling broader fluid analysis.[3][5]
Expect influence to grow via pharma collaborations for therapy development and global clinic adoption, evolving from niche scanner to foundational cellular health infrastructure—illuminating cells to connect insights directly to patient outcomes, as its core mission promises.[1][5]
illumicell AI has raised $300K across 1 funding round. Most recently, it raised $300K Seed in October 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2023 | $300K Seed | Arix Bioscience, Canaan Partners |